期刊文献+

髓复康对大鼠脑缺血损伤区内勿动蛋白(NoGo-A)表达的影响 被引量:1

Effect of Chinese Herb Suifukang on Expression of NoGo-A Protein in the Brain of MACO Rat
原文传递
导出
摘要 目的研究益气活血补肾方髓复康对大鼠脑缺血损伤区勿动蛋白(NoGo-A)表达的抑制作用。方法通过Koizumi法制作SD大鼠单侧大脑中动脉阻塞模型(MACO),将SD大鼠随机分为正常组、模型组、阳性对照组、髓复康大剂量组、中剂量组和小剂量组,各组又分别在给药8、15和30 d 3个时间点取大鼠脑组织,通过免疫组化、RT-PCR的方法检测各组脑缺血损伤区勿动蛋白表达量的差异。结果中药大剂量及中剂量组勿动蛋白表达最弱,均与模型组形成极显著差异(P<0.001),小剂量组的勿动蛋白表达也低于模型组,与之形成显著差异(P<0.05)。结论髓复康可以抑制脑缺血损伤区勿动蛋白的表达,改善脑缺血损伤区轴突再生微环境,可能是其促进脑缺血损伤后轴突再生的机制之一。 OBJECTIVE To study the effect of Chinese herb Suifukang on the expression of Nogo protein-A in the brain of MCAO rats and explore the action mechanism of its promoting neurogenesis. METHODS SD rats were selected and randomized into six groups : normal group, control group, treatment group of methylprednisolone, treatment group of Chinese herb Suifukang in large-does, middle-does and small-does. The models of MCAO rats were successfully established by the method of Koizumi. After the surgery, the rats of drug group had been taken orally Suifukang by 10 g · kg-1 crude drug one time daily, and the rest groups had been taken orally equivalence saline once a day. The brain of rats were investigated and the expression of NoGo-A was detected by immunohistology method and RT-PCR method. RESULTS The expression of NoGo-A in the injured brain was apparently inhibited by Suifukang(P 〈 0. 01 ). CONCLUSION Suifukang can inhibit the expression of NoGo-A. So this function may be one of the mechanisms that Suifukang can promote the functional recovery after brain injury.
出处 《中国药学杂志》 CAS CSCD 北大核心 2013年第1期35-38,共4页 Chinese Pharmaceutical Journal
基金 国家自然科学基金资助项目(30701094)
关键词 髓复康 脑缺血损伤 勿动蛋白 免疫组织化学 Suifukang brain injury NoGo-A immunohistology
  • 相关文献

参考文献2

二级参考文献38

  • 1Iqbal K, Alonso-Adel C, El-Akkad E, etal. Pharmacological targets to inhibit Alzheimer neurofibrillary degeneration [ J ]. J Neural Transm, 2002, (62) :309.
  • 2Lau LF, Schachter JB, Seymour PA, et al. Tau protein phosphorylation as a therapeutic target in Alzheimer's disease[J]. Curr Top Med Chem, 2002 ,2(4) :395.
  • 3Hamdane M, Smet C, Sambo AV, et al. Pinl: a therapeutic target in Alzheimer neurodegeneration [J]. J Mol Neurosci ,2002,19(3):275.
  • 4Lau LF, Seymour PA, Sanner MA, et al. Cdk5 as a drug target for the treatment of Alzheimer's disease [J]. JMol Neurosci, 2002 ,19(3) :267.
  • 5Tsai JY, Wolfe MS, Xia W. The search for gamma-secretase and development of inhibitors [J]. Curr Med Chem, 2002,9(11) :1087.
  • 6Vassar R. Beta-Secretase (BACE) as a drug target for Alzheimer's disease [J]. Adv Drug Deliv Rev, 2002 ,54(12) :1589.
  • 7Adessi C, Frossard MJ, Boissard C, et al. Pharmacological profiles of peptide drug candidates for the treatment of Alzheimer's disease[J]. JBiol Chem,2003 ,278(16) :13905.
  • 8Matsuoka Y, Saito M, LaFrancois J, et al. Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to beta-amyloid [ J ]. J Neurosci,2003 ,23(1) :29.
  • 9Pasinetti GM. Cyclooxygenase as a target for the antiamyloidogenic activities of nonsteroidal anti-inflammatory drugs in Alzheimer's disease[J]. Neurosignals, 2002 ,11(5) :293.
  • 10Lee HG, Zhu X, Ghanbari HA, et al. Differential regulation of glutamate receptors in Alzheimer's disease [ J]. Neurosignals, 2002 , 11(5) :282.

共引文献8

同被引文献23

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部